CETP inhibitors

US8193365B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Amjad Ali · Freehold, US
• Joann Bohn · North Plainfield, US
• Qiaolin Deng · Edison, US
• Zhijian Lu · Clinton, US
• Peter J. Sinclair · Highland Park, US
• Gayle E. Taylor · Jersey City, US
• Christopher F. Thompson · Arlington, US
• Nazia Quraishi · Bethesda, US

Key dates

• Filing date: Jun 14, 2010
• Grant date: Jun 5, 2012
• Expiry date: Jun 14, 2030

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, A1 and A2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused to a heterocyclic ring, a phenyl ring fused to a heterocyclic ring, or a cycloalkyl ring.